Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Recent data on eribulin in metastatic breast cancer patients from SABCS 2018

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.18
Views: 2830

Professor Chris Twelves and Dr Giampaolo Bianchini

Professor Chris Twelves and Dr Giampaolo Bianchini meet in San Antonio at the San Antonio Breast Cancer Symposium 2018 annual conference for an educational breast cancer expert-to-expert discussion. The talk covers the latest data seen for eribulin use in metastatic breast cancer patients.

The talk is opened with a brief summary of eribulin’s unique mechanism of action - its antiproliferative cytotoxic activity and other effects including its remodelling of tumour vasculature, its impact on epithelial-mesenchymal transition and on migration metastases.

They then go on to discuss a specific recent paper of eribulin’s effects on tumour remodelling. Here they discuss the overall survival benefit of the drug, and its specific actions of increasing epithelial markers and impacting epithelial-mesenchymal transition that is not seen with other microtubule inhibitors. Prof Twelves then relates this to a recent in vivo study looking at animal exposure to microtubule inhibitors and the changes seen in epithelial and mesenchymal markers.

The experts then discuss the importance of understanding how chemotherapy works, with reference to the recent improving knowledge surrounding eribulin’s mechanism of action.

Dr Bianchini then asks Prof Twelves to comment on his opinion of using eribulin in combination with other agents outside standard treatment guidelines, with reference to a recent study looking at eribulin in combination with trastuzumab.

The pair then discuss the potential to use eribulin in combination with other therapies, including capcitabine, immune agents such as pembrolizumab and rebastinib; commenting on recent data and how the drug’s additional biological modes of action allow it to be a good combination partner.

The discussion is finalised with the experts discussing what can be expected of chemotherapy usage in future years.

Biological effects of eribulin
Evidence of eribulin's efficacy
Eribulin's mechanism of action
The combination of eribulin with trastuzumab
The combination of eribulin with other immunological agents
Further uses of eribulin

This programme has been supported by an unrestricted educational grant from Eisai

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation